Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS3
2008-008323-15Phase 2Completed
- Sponsor
- Medical Research Council
- Start
- May 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan, fluorouracil, folinic acid, oxaliplatin, cetuximab and 2 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Medical Research Council. Primary endpoint: Feasibility of timely molecular results. Started May 2009; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acidoxaliplatincetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-008323-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008323-15.